Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06889766 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

Study acronym: LauT1
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: 2 to 3
    • Eligibility criteria shortened, about 6 words
    • Secondary endpoints revised (5)
    • Study description expanded, about 65 words
    v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary endpoints revised (2)
    • Study sites: 1 to 2
    • Start date changed from estimate of Mar 14, 2025 to Mar 24, 2025
    • Secondary endpoints revised (5)
    • Study title shortened, about 25 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A single center, dose escalaion, Phase I clinical trial to demonstrate safety and efficacy of LauT-1, autologous "New York Esophageal Squamous Cell Carcinoma-1 T-Cell Receptor (NY-ESO-1 TCR)-directed T cells in combination with non-myeloablative (NMA) lymphodepleting chemotherapy and low dose irradiation (LDI) in patients with NY-ESO-1 positive sarcoma and melanoma.
Trial Details
NCT Number NCT06889766
Lead Sponsor Centre Hospitalier Universitaire Vaudois
Conditions
(from sponsor)		 Advanced Melanoma, Melanoma Metastatic, Sarcoma
Related terms Melanoma, Sarcoma
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov